Anlon Healthcare Ltd
Incorporated in 2013, Anlon Healthcare Limited is a chemical manufacturing company engaged in the manufacturing of Pharma Intermediates and active pharmaceutical ingredients (APIs).[1]
- Market Cap ₹ 1,466 Cr.
- Current Price ₹ 27.6
- High / Low ₹ 37.6 / 10.3
- Stock P/E 46.4
- Book Value ₹ 4.33
- Dividend Yield 0.00 %
- ROCE 20.8 %
- ROE 18.4 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has high debtors of 220 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare Nifty IPO
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| 120 | 172 | |
| 88 | 124 | |
| Operating Profit | 32 | 48 |
| OPM % | 27% | 28% |
| 0 | 0 | |
| Interest | 4 | 4 |
| Depreciation | 2 | 2 |
| Profit before tax | 27 | 43 |
| Tax % | 24% | 32% |
| 21 | 29 | |
| EPS in Rs | 0.51 | 0.54 |
| Dividend Payout % | -0% | -0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 43% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 39% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 117% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 18% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 40 | 53 |
| Reserves | 41 | 177 |
| 67 | 44 | |
| 34 | 100 | |
| Total Liabilities | 181 | 374 |
| 23 | 58 | |
| CWIP | -0 | -0 |
| Investments | 1 | 1 |
| 158 | 315 | |
| Total Assets | 181 | 374 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| -22 | -59 | |
| 2 | -36 | |
| 19 | 118 | |
| Net Cash Flow | -1 | 23 |
| Free Cash Flow | -19 | -95 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | -85% | -114% |
Ratios
Consolidated / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Debtor Days | 228 | 220 |
| Inventory Days | 246 | 393 |
| Days Payable | 96 | 147 |
| Cash Conversion Cycle | 377 | 467 |
| Working Capital Days | 292 | 417 |
| ROCE % | 21% |
Insights
In beta| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Capacity Utilization % ・Standalone data |
|
||||
| Commercialized Products count ・Standalone data |
|||||
| Customers Served count ・Standalone data |
|||||
| Installed Capacity MTPA ・Standalone data |
|||||
| API Revenue Share % ・Standalone data |
|||||
| CDMO Molecules in Development count ・Standalone data |
|||||
| DMF Filings (Cumulative) count ・Standalone data |
|||||
Extracted by Screener AI
Documents
Announcements
-
Board Meeting Outcome for Outcome Of Board Meeting Of ANLON HEALTHCARE LIMITED
- Board approved preferential issue of convertible warrants up to ₹250 crore to four investors.
-
Board Meeting Intimation for Company''s Business Expansion Plans In India And/Or Overseas, And The Raising Of Funds/ Financing Thereof, In One Or More Tranches,
- Board meeting on 13 Oct 2026 to discuss expansion plans and potential fund raising.
-
Closure of Trading Window
- Trading window closes from October 1, 2026 until 48 hours after Q2 and H1 results.
-
Intimation Of Participation In Arihant Capital 'BHARAT CONNECT CONFERENCE RISING STARS 2026' Under Regulation 30 Of SEBI (LODR) Regulations, 2015
- Management will participate in Arihant Capital’s Bharat Connect Conference Rising Stars 2026 on 29 September 2026.
-
Announcement For Incorporation Of Foreign Subsidiary Of The Company
- Anlon Healthcare incorporated 90%-owned Nigeria subsidiary on September 20, 2026 to expand West African operations.
Concalls
-
Aug 2026Transcript PPT
-
Jun 2026Transcript PPT REC
-
Feb 2026Transcript PPT
-
Nov 2025Transcript PPT REC
Business Profile:[1]
Anlon Healthcare is a chemical manufacturing company engaged in:
a) Pharmaceutical Intermediates:
High-purity intermediates used as
raw material/starting material in APIs.
b) Active Pharmaceutical Ingredients::
Raw material for finished dosage formulations (tablets, capsules, ointments, syrups, etc.), nutraceuticals, personal care, and veterinary products.
c) Custom manufacturing/CDMO:
Development and manufacturing of complex
and novel chemical compounds, including high-purity chemicals.
The company is working on three molecules
for two global innovator companies under
its CDMO/custom-manufacturing business:
- One molecule had entered validation, with commercial supplies targeted from Q3 FY27.
- The other 2 were expected to enter validation during Q2 FY27.
- Their commercialisation was targeted for Q4 FY27 or Q1 FY28.[2]